Market Summary
USD0.33-0.00
Market Closedas of 21 Sep 2023, 09:31 am0.00%
IBIO Stock Price
IBIO RSI Chart
IBIO Valuation
IBIO Price/Sales (Trailing)
IBIO Profitability
IBIO Fundamentals
IBIO Revenue
IBIO Earnings
Price Action
52 Week Range
0.269.25
(Low)(High)
Last 7 days
-16.4%
Last 30 days
-12.3%
Last 90 days
-49.0%
Trailing 12 Months
-96.1%
IBIO Financial Health
IBIO Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for IBIO
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-08-28 | Brenner Martin | sold | -1,528 | 0.3051 | -5,011 | see remarks |
2023-07-27 | Brenner Martin | sold | -2,307 | 0.511091 | -4,515 | see remarks |
2023-07-12 | Brenner Martin | sold | -27,520 | 0.5853 | -47,020 | see remarks |
2023-06-26 | Brenner Martin | acquired | - | - | 75,833 | see remarks |
2023-06-22 | Brenner Martin | back to issuer | - | - | -75,833 | see remarks |
2023-06-21 | Brenner Martin | sold | -2,848 | 0.680898 | -4,184 | see remarks |
2023-05-22 | Brenner Martin | sold | -3,910 | 0.935057 | -4,182 | see remarks |
2023-04-24 | Brenner Martin | sold | -5,257 | 1.1998 | -4,382 | see remarks |
2023-03-31 | Duran Felipe | acquired | - | - | 37,500 | chief financial officer |
2023-03-31 | Brenner Martin | acquired | - | - | 50,000 | see remarks |
Which funds bought or sold IBIO recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-08-21 | OSAIC HOLDINGS, INC. | added | 4.95 | -698 | 308 | -% |
2023-08-15 | HARBOUR INVESTMENTS, INC. | unchanged | - | -1,176 | 488 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 13.00 | -139 | 69.00 | -% |
2023-08-15 | Retirement Group, LLC | new | - | 174 | 174 | -% |
2023-08-15 | Belpointe Asset Management LLC | sold off | -100 | -1,706 | - | -% |
2023-08-14 | CITADEL ADVISORS LLC | added | 165 | -3,488 | 12,208 | -% |
2023-08-14 | Royal Bank of Canada | reduced | -74.14 | -5,000 | - | -% |
2023-08-14 | VANGUARD GROUP INC | reduced | -1.35 | -767,590 | 312,493 | -% |
2023-08-14 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | sold off | -100 | -52,000 | - | -% |
2023-08-14 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | new | - | 49.00 | 49.00 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Ibio
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 5.28% | 475,593 | SC 13G | |
| Jul 08, 2022 | blackrock inc. | 1.8% | 3,960,718 | SC 13G | |
| Feb 03, 2022 | blackrock inc. | 7.1% | 15,476,683 | SC 13G/A | |
| Feb 02, 2021 | blackrock inc. | 5.5% | 11,575,051 | SC 13G | |
| Aug 13, 2020 | eastern capital ltd | 0.6% | 1e+06 | SC 13D/A | |
| Aug 11, 2020 | eastern capital ltd | 5.8% | 8,629,693 | SC 13D/A | |
| Aug 07, 2020 | eastern capital ltd | 22.3% | 33,114,597 | SC 13D/A | |
| Aug 06, 2020 | eastern capital ltd | 22.3% | 33,114,597 | SC 13D/A | |
| Mar 31, 2020 | eastern capital ltd | 28.7% | 37,382,734 | SC 13D/A | |
| Mar 05, 2020 | eastern capital ltd | 35.6% | 37,382,734 | SC 13D/A |
Recent SEC filings of Ibio
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 30, 2023 | 4 | Insider Trading | |
| Aug 24, 2023 | 4 | Insider Trading | |
| Aug 24, 2023 | 4 | Insider Trading | |
| Aug 15, 2023 | D | D | |
| Aug 14, 2023 | 424B3 | Prospectus Filed | |
| Aug 11, 2023 | EFFECT | EFFECT | |
| Aug 10, 2023 | CORRESP | CORRESP | |
| Aug 09, 2023 | UPLOAD | UPLOAD | |
| Aug 07, 2023 | 8-K | Current Report | |
| Aug 07, 2023 | 424B5 | Prospectus Filed |
Peers (Alternatives to Ibio)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AMGN | 145.2B | 26.6B | 4.13% | 21.09% | 18.2 | 5.46 | 0.75% | 21.34% |
GILD | 94.5B | 27.4B | -0.16% | 19.51% | 17.24 | 3.45 | -0.48% | 32.56% |
MRNA | 39.4B | 10.7B | -6.80% | -20.18% | 32.68 | 3.7 | -53.67% | -91.41% |
BIIB | 37.7B | 10.0B | -1.71% | 27.59% | 14.15 | 3.78 | -6.23% | 29.40% |
| MID-CAP | ||||||||
NBIX | 11.2B | 1.7B | 5.59% | 6.81% | 63.29 | 6.67 | 29.01% | 1345.90% |
BBIO | 4.5B | - | -3.04% | 140.92% | -7.66 | 48.33 | 54.84% | -12.96% |
DNLI | 3.1B | - | -4.51% | -22.98% | -23.78 | 37.44 | 122.90% | 54.78% |
BEAM | 2.0B | 80.2M | 6.46% | -52.82% | -6.01 | 24.54 | 42.17% | -39.82% |
| SMALL-CAP | ||||||||
RCUS | 1.5B | 121.2M | 4.38% | -25.42% | -5.13 | 12.17 | -70.36% | -531.73% |
REPL | 980.2M | 15.3M | -15.63% | 3.04% | -5.4 | 64.02 | 1090.59% | -36.57% |
NVAX | 664.9M | 1.6B | -12.64% | -74.33% | -1.13 | 0.42 | 23.74% | 60.24% |
FATE | 221.7M | - | -17.58% | -90.72% | -1.05 | 1.62 | 116.83% | 16.61% |
SGMO | 146.7M | - | -8.84% | -84.12% | -0.74 | 0.61 | 113.96% | -15.19% |
VXRT | 112.7M | 2.1M | -6.14% | -67.90% | -1.12 | 54.83 | 487.70% | -8.66% |
IBIO | 4.1M | - | -12.28% | -96.10% | -0.05 | 3.21 | - | -129.46% |
Ibio News
Returns for IBIO
Cumulative Returns on IBIO
-44.8%
10-Year Cumulative Returns
-57.7%
7-Year Cumulative Returns
-56.9%
5-Year Cumulative Returns
-82.5%
3-Year Cumulative Returns
Risks for IBIO
What is the probability of a big loss on IBIO?
100%
Probability that Ibio stock will be more than 20% underwater in next one year
100%
Probability that Ibio stock will be more than 30% underwater in next one year.
93.8%
Probability that Ibio stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does IBIO drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Ibio was unfortunately bought at previous high price.
Drawdowns
Financials for Ibio
Income Statement (Last 12 Months)(In Thousands)
| Income Statement (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 | 2017Q4 |
| Revenue | - | - | - | 2,383 | 2,543 | 1,508 | 2,045 | 2,371 | 3,000 | 2,331 | 1,940 | 1,638 | 1,313 | 1,744 | 2,081 | 2,018 | 1,314 | 865 | 367 | 444 | 500 | 459 |
| Gross Profit | - | - | - | 2,167 | 2,425 | 802 | 1,241 | 909 | 1,890 | 1,628 | 1,512 | 935 | 40.00 | - | - | - | - | - | - | - | - | - |
| Operating Expenses | -4.2% | 55,107 | 57,526 | 51,857 | 30,871 | 29,758 | 30,566 | 32,020 | 26,491 | 23,090 | 18,520 | 14,938 | 16,354 | 16,577 | 17,774 | 17,806 | 16,995 | 16,269 | 15,183 | 14,671 | 14,640 | 15,042 |
| S&GA Expenses | -4.8% | 35,672 | 37,463 | 34,128 | 21,509 | 21,506 | 21,799 | 22,031 | 19,510 | 17,176 | 14,092 | 11,365 | 11,770 | 11,635 | 12,447 | 12,332 | 12,103 | 11,864 | 11,058 | 10,685 | 10,584 | 10,816 |
| R&D Expenses | -3.1% | 19,435 | 20,063 | 17,729 | 9,362 | 8,252 | 8,767 | 9,989 | 6,981 | 5,914 | 4,428 | 3,573 | 4,584 | 4,942 | 5,327 | 5,474 | 4,892 | 4,405 | 4,125 | 3,986 | 4,056 | 4,226 |
| Interest Expenses | 4.5% | 805 | 770 | 1,412 | 1,223 | 1,835 | 2,450 | 2,454 | 2,456 | 2,460 | 2,460 | 2,466 | 2,325 | 2,183 | 2,044 | 1,900 | 1,904 | 1,908 | 1,911 | 1,915 | 1,919 | 1,922 |
| Net Income | 6.3% | -76,030 | -81,126 | -50,303 | -33,134 | -28,405 | -24,616 | -23,207 | -26,864 | -23,879 | -19,512 | -16,439 | -17,407 | -16,954 | -17,660 | -17,593 | -17,510 | -17,249 | -16,679 | -16,105 | -8,364 | -8,315 |
| Net Income Margin | - | - | - | -21.11* | -3.25* | -2.78* | -2.41* | -2.28* | -8.95* | -10.24* | -10.06* | -10.04* | -13.26* | -9.72* | -8.49* | -8.72* | - | - | - | - | - | - |
| Free Cashflow | 6.0% | -45,631 | -48,548 | -44,810 | -39,617 | -41,371 | -37,965 | -34,984 | -29,918 | -25,431 | -19,625 | -14,423 | -14,285 | -14,693 | -16,130 | - | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
| Assets | -14.3% | 44.00 | 52.00 | 85.00 | 99.00 | 115 | 126 | 144 | 147 | 143 | 145 | 117 | 94.00 | 42.00 | 36.00 | 35.00 | 31.00 | 36.00 | 40.00 | 43.00 | 43.00 | 31.00 |
| Current Assets | -29.1% | 27.00 | 38.00 | 64.00 | 45.00 | 60.00 | 67.00 | 90.00 | 105 | 107 | 111 | 85.00 | 62.00 | 10.00 | 4.00 | 2.00 | 5.00 | 10.00 | 14.00 | 16.00 | 16.00 | 4.00 |
| Cash Equivalents | 77.5% | 7.00 | 4.00 | 10.00 | 23.00 | 40.00 | 45.00 | 63.00 | 77.00 | 85.00 | 91.00 | 78.00 | 55.00 | 10.00 | 4.00 | 2.00 | 4.00 | 9.00 | 13.00 | 8.00 | 4.00 | 3.00 |
| Inventory | - | - | - | - | 4.00 | 3.00 | 2.00 | 1.00 | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net PPE | 2.7% | 4.00 | 4.00 | 3.00 | 1.00 | 35.00 | 33.00 | 10.00 | 9.00 | 6.00 | 5.00 | 4.00 | 4.00 | 3.00 | 3.00 | 3.00 | 24.00 | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 |
| Liabilities | -18.1% | 27.00 | 33.00 | 36.00 | 36.00 | 36.00 | 36.00 | 43.00 | 38.00 | 38.00 | 38.00 | 37.00 | 38.00 | 38.00 | 37.00 | 37.00 | 28.00 | 29.00 | 29.00 | 30.00 | 27.00 | 27.00 |
| Current Liabilities | -19.8% | 22.00 | 28.00 | 32.00 | 30.00 | 8.00 | 8.00 | 8.00 | 7.00 | 6.00 | 6.00 | 5.00 | 5.00 | 6.00 | 5.00 | 5.00 | 3.00 | 4.00 | 4.00 | 5.00 | 2.00 | 2.00 |
| Shareholder's Equity | -7.6% | 17.00 | 19.00 | 48.00 | 63.00 | 79.00 | 91.00 | 101 | 109 | 105 | 107 | 80.00 | 57.00 | 4.00 | - | - | 2.00 | 7.00 | 11.00 | 13.00 | 16.00 | 4.00 |
| Retained Earnings | -2.6% | -282 | -275 | -242 | -223 | -206 | -194 | -182 | -173 | -173 | -166 | -157 | -150 | -146 | -135 | -110 | -105 | -101 | -97.09 | -92.63 | -88.23 | -83.81 |
| Additional Paid-In Capital | 1.9% | 300 | 295 | 291 | 288 | 286 | 285 | 283 | 282 | 278 | 273 | 238 | 207 | 151 | 135 | 108 | 108 | 108 | 108 | 106 | 104 | 88.00 |
| Shares Outstanding | 0% | 12.00 | 12.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 9.00 | 8.00 | 6.00 | 6.00 | 4.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 |
| Minority Interest | - | - | - | - | - | - | - | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Last 12 Months) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 | 2018Q1 |
| Cashflow From Operations | 5.3% | -36,969 | -39,041 | -42,092 | -37,480 | -33,203 | -34,608 | -32,341 | -30,064 | -26,705 | -23,142 | -18,128 | -13,345 | -13,870 | -14,219 | -15,484 | -13,975 | -12,958 | -12,323 | -11,241 | -13,480 | -13,870 |
| Share Based Compensation | 6.7% | 5,124 | 4,802 | 4,778 | 4,377 | 3,794 | 2,894 | 2,056 | 1,586 | 1,210 | 899 | 671 | 388 | 227 | 213 | 236 | 241 | 375 | 509 | 638 | 770 | 874 |
| Cashflow From Investing | 3329.3% | 7,492 | -232 | 51.00 | -5,127 | -8,512 | -13,043 | -25,027 | -26,478 | -24,390 | -20,472 | -7,724 | -1,154 | -507 | -550 | -731 | -990 | -1,099 | -1,445 | -1,257 | -1,079 | -1,322 |
| Cashflow From Financing | 76.7% | -449 | -1,923 | -4,896 | -6,125 | -3,203 | 1,545 | 42,646 | 78,835 | 125,682 | 131,231 | 101,293 | 65,192 | 15,383 | 5,046 | 2,310 | 3,453 | 19,695 | 19,820 | 22,593 | 22,406 | 6,170 |
IBIO Income Statement
2022-12-31Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2022 | Dec. 31, 2021 | |
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||
| Revenues | $ 0 | $ 0 | $ 84 | |
| Operating expenses: | ||||
| Research and development | 2,779 | 1,859 | $ 5,327 | 2,993 |
| General and administrative | 7,794 | 5,372 | 12,882 | 9,547 |
| Total operating expenses | 10,573 | 7,231 | 18,209 | 12,540 |
| Operating loss | (10,573) | (7,231) | (18,209) | (12,456) |
| Other income (expense): | ||||
| Interest expense | (31) | 0 | (31) | |
| Interest income | 41 | 35 | 140 | 71 |
| Royalty income | 0 | 5 | 5 | |
| Total other income (expense) | 10 | 40 | 109 | 76 |
| Consolidated net loss from continuing operations | (10,563) | (7,191) | (18,100) | (12,380) |
| Net loss attributable to noncontrolling interest | 0 | 0 | 1 | |
| Net loss attributable to iBio, Inc. from continuing operations | (10,563) | (7,191) | (18,100) | (12,379) |
| Preferred stock dividends - iBio CDMO Tracking Stock | 0 | (22) | 0 | (88) |
| Net loss available to iBio, Inc. stockholders from continuing operations | (10,563) | (7,213) | (18,100) | (12,467) |
| Loss from discontinued operations | (22,990) | (4,729) | (33,583) | (8,480) |
| Net loss available to iBio, Inc. stockholders | (33,553) | (11,942) | (51,683) | (20,947) |
| Comprehensive loss: | ||||
| Consolidated net loss | (33,553) | (11,920) | (51,683) | (20,860) |
| Other comprehensive loss - unrealized gain ( loss) on debt securities | 56 | (27) | 46 | (28) |
| Comprehensive loss | $ (33,497) | $ (11,947) | $ (51,637) | $ (20,888) |
| Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations | $ (1.08) | $ (0.83) | $ (1.94) | $ (1.43) |
| Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations | (1.08) | (0.83) | (1.94) | (1.43) |
| Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations | (2.34) | (0.54) | (3.60) | (0.97) |
| Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations | (2.34) | (0.54) | (3.60) | (0.97) |
| Loss per common share attributable to iBio, Inc. stockholders - basic - total | (3.42) | (1.37) | (5.54) | (2.40) |
| Loss per common share attributable to iBio, Inc. stockholders - diluted - total | $ (3.42) | $ (1.37) | $ (5.54) | $ (2.40) |
| Weighted-average common shares outstanding - basic | 9,807 | 8,715 | 9,324 | 8,715 |
| Weighted-average common shares outstanding - diluted | 9,807 | 8,715 | 9,324 | 8,715 |
IBIO Balance Sheet
2022-12-31Condensed Consolidated Balance Sheets - USD ($) | Dec. 31, 2022 | Jun. 30, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 3,696,000 | $ 22,676,000 |
| Investments in debt securities | 5,929,000 | 10,845,000 |
| Accounts receivable - trade | 970,000 | 1,000,000 |
| Settlement receivable - current portion | 5,100,000 | 5,100,000 |
| Convertible promissory note receivable and accrued interest | 1,669,000 | |
| Prepaid expenses and other current assets | 414,000 | 1,549,000 |
| Current assets held for sale | 20,457,000 | 3,900,000 |
| Total Current Assets | 38,235,000 | 45,070,000 |
| Restricted cash | 253,000 | 5,996,000 |
| Convertible promissory note receivable and accrued interest | 1,631,000 | |
| Finance lease right-of-use assets, net of accumulated amortization | 746,000 | |
| Operating lease right-of-use asset | 2,873,000 | 3,068,000 |
| Fixed assets, net of accumulated depreciation | 4,245,000 | 1,373,000 |
| Intangible assets, net of accumulated amortization | 5,398,000 | 4,851,000 |
| Security deposits | 50,000 | 29,000 |
| Prepaid expenses - noncurrent | 74,000 | |
| Noncurrent assets held for sale | 37,314,000 | |
| Total Assets | 51,800,000 | 99,406,000 |
| Current liabilities: | ||
| Accounts payable | 4,002,000 | 4,264,000 |
| Accrued expenses | 5,001,000 | 3,764,000 |
| Finance lease obligations - current portion | 259,000 | |
| Operating lease obligation - current portion | 315,000 | 91,000 |
| Equipment financing payable - current portion | 152,000 | |
| Term note payable - net of deferred financing costs | 16,011,000 | 22,161,000 |
| Contract liabilities | 88,000 | 100,000 |
| Current liabilities related to assets held for sale | 1,947,000 | 56,000 |
| Total Current Liabilities | 27,775,000 | 30,436,000 |
| Finance lease obligations - net of current portion | 490,000 | |
| Operating lease obligation - net of current portion | 3,324,000 | 3,514,000 |
| Equipment financing payable - net of current portion | 323,000 | |
| Accrued expenses - noncurrent | 1,065,000 | |
| Noncurrent liabilities related to assets held for sale | 1,971,000 | |
| Total Liabilities | 32,977,000 | 35,921,000 |
| iBio, Inc. Stockholders' Equity: | ||
| Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized; 0 and 1,000 shares issued and outstanding as of December 31, 2022 and June 30, 2022, respectively | ||
| Common stock - $0.001 par value; 275,000,000 shares authorized at December 31, 2022 and June 30, 2022; 12,368,287 and 8,727,158 shares issued and outstanding as of December 31, 2022 and June 30, 2022, respectively | 12,000 | 9,000 |
| Additional paid-in capital | 294,591,000 | 287,619,000 |
| Accumulated other comprehensive loss | (167,000) | (213,000) |
| Accumulated deficit | (275,613,000) | (223,930,000) |
| Total iBio, Inc. Stockholders' Equity | 18,823,000 | 63,485,000 |
| Total Liabilities and Equity | $ 51,800,000 | $ 99,406,000 |
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.